RESUMEN

Deep Learning Automated Patient-Specific Quality Assurance (PSQA) aims to reduce clinical resource requirements. It is vital to ensure the safety and effectiveness of radiation therapy by predicting the dose difference metric (Gamma passing rate) and its distribution. However, current research overlooks uncertainty quantification in model predictions, limiting their trustworthiness in real clinical environments. This paper proposes a Multi-granularity Uncertainty Quantification (MGUQ) framework. A Bayesian framework that quantifies uncertainties at multiple granularities for multi-task PSQA, specifically Gamma Passing Rate (GPR) prediction and Dose Difference Prediction (DDP), integrates visualization-based interactive components. Using Bayesian theory, we derive a comprehensive multi-granularity loss function that comprises granularity-specific loss and coherence loss components. Additionally, we proposed Multi-granularity Prior Networks, a dual-stream network architecture, to infer the distributions of DDP (modeled as t-distributions) and GPR (modeled as Gaussian distributions) under specific statistical assumptions. Comprehensive evaluations are conducted on a dataset from ''Peeking Union Medical College Hospital'', and results show that our proposed method achieves a minimum MAE loss of 0.864 with a 2%/3 mm criterion and realizes the uncertainty visualization of dose difference. Further, it also achieves 100% Clinical Accuracy (CA) with a workload of 67.2%. Experiments demonstrate that the proposed framework can enhance the trustworthiness of deep learning applications in PSQA.

Asunto(s)

RESUMEN

BACKGROUND: It has been observed that under the single isocenter conditions, the potential shifts of the electronic portal imaging devices (EPID) may be introduced when executing portal dosimetry (PD) plans for bilateral breast cancer, pleural mesothelioma, and lymphoma. These shifts are relative to the calibration positions of EPID and result in significant discrepancies in the plan verification results. PURPOSE: To explore methods including correction model and specific correction matrices to revise the data obtained from displaced EPID. METHODS: Two methods, the correction model and the specific correction matrices, were applied to correct the data. Five experiments were designed and conducted to build correction model and to validate the effectiveness of these two methods. Gamma passing rates were calculated and data profiles along X-axis and Y-axis were captured. RESULTS: The gamma passing rates for the EPID-displaced IMRT validation plans after applying correction model, along with the application of specific correction matrices to VMAT and IMRT validation plans, exhibit results that are comparable to the cases with non-displaced EPID. Except for the VMAT plans applied correction model which showed larger discrepancies (0.041 ± 0.028, 0.049 ± 0.030), the other three exhibit minimal differences in discrepancy values. In all profiles, the corrected data from displaced EPID exhibit a high level of agreement with data obtained from non-displaced EPID. Good consistency is observed in actual application of the correction model and the specific correction matrices between gamma passing rates of data corrected and those of non-displaced data. CONCLUSIONS: The proposed methods involving correction model and specific correction matrices can correct the data collected from the displaced EPID, and the gamma passing rates of the corrected data show results that are comparable to some extent with those of non-displaced data. Particularly, the results corrected by specific correction matrices closely resemble the data from non-displaced EPID.

Asunto(s)

RESUMEN

Create a virtual ArcCHECK-MR phantom, customized for a 1.5T MR-linac, with consideration of the different density regions within the quality assurance (QA) phantom, aiming to streamline the utilization of this specialized QA device. A virtual phantom was constructed in the treatment planning system (TPS) to replicate the ArcCHECK-MR's composition, consisting of five distinct layers: "Outer" (representing the outer PMMA ring), "Complex" (simulating the printed circuit boards), "Detectors" (encompassing the detector area), "Inner" (signifying the inner PMMA ring) and "Insert" (representing the PMMA insert). These layers were defined based on geometric data and represented as contour points on a set of dummy CT images. Additionally, a setup platform was integrated as contoured structures. To determine the relative electron density (RED) values of the external and internal PMMA components, measurements were taken at 25 points in the insert using an ion chamber. A novel method for establishing the exit/entrance dose ratio (EEDR) for ArcCHECK-MR was introduced. The RED of higher density region was derived by evaluating the local gamma index passing rate results with criteria of 2% dose difference and 2 mm distance-to-agreement. The performance of the virtual phantom was assessed for Unity 7 FFF beams with a 1.5T magnetic field. The radii of the five ring structures within the virtual phantom measured 133.0 mm, 110.0 mm, 103.4 mm, 100.0 mm, and 75.0 mm for the "Outer," "Complex," "Detectors," "Inner" and "Insert" regions, respectively. The RED values were as follows: ArcCHECK-MR PMMA had a RED of 1.130, "Detectors" were assumed to have a RED of 1.000, "Complex" had a RED of 1.200, and the setup QA phantom justified a RED of 1.350. Early validation results demonstrate that the 5-layer virtual phantom, when compared to the commonly used bulk overridden phantom, offers improved capability in MR-linac environments. This enhancement led to an increase in passing rates for the local gamma index by approximately 5 ∼ 6%, when applying the criteria of 2%, 2 mm. We have successfully generated a virtual representation of the distinct regions within the ArcCHECK-MR using a TPS, addressing the challenges associated with its use in conjunction with a 1.5T MR-linac. We consistently observed favorable local gamma index passing rates across two 1.5T MR-linac and ArcCHECK-MR unit combinations. This approach has the potential to minimize uncertainties in the creation of the QA phantom for ArcCHECK-MR across various institutions.

Asunto(s)

RESUMEN

BACKGROUND: Plan verification is one of the important steps of quality assurance (QA) in carbon ion radiotherapy. Conventional methods of plan verification are based on phantom measurement, which is labor-intensive and time-consuming. Although the plan verification method based on Monte Carlo (MC) simulation provides a more accurate modeling of the physics, it is also time-consuming when simulating with a large number of particles. Therefore, how to ensure the accuracy of simulation results while reducing simulation time is the current difficulty and focus. PURPOSE: The purpose of this work was to evaluate the feasibility of using deep learning-based MC denoising method to accelerate carbon-ion radiotherapy plan verification. METHODS: Three models, including CycleGAN, 3DUNet and GhostUNet with Ghost module, were used to denoise the 1 × 106 carbon ions-based MC dose distribution to the accuracy of 1 × 108 carbon ions-based dose distribution. The CycleGAN's generator, 3DUNet and GhostUNet were all derived from the 3DUNet network. A total of 59 cases including 29 patients with head-and-neck cancers and 30 patients with lung cancers were collected, and 48 cases were randomly selected as the training set of the CycleGAN network and six cases as the test set. For the 3DUNet and GhostUNet models, the numbers of training set, validation set, and test set were 47, 6, and 6, respectively. Finally, the three models were evaluated qualitatively and quantitatively using RMSE and three-dimensional gamma analysis (3 mm, 3%). RESULTS: The three end-to-end trained models could be used for denoising the 1 × 106 carbon ions-based dose distribution, and their generalization was proved. The GhostUNet obtained the lowest RMSE value of 0.075, indicating the smallest difference between its denoised and 1 × 108 carbon ions-based dose distributions. The average gamma passing rate (GPR) between the GhostUNet denoising-based versus 1 × 108 carbon ions-based dose distributions was 99.1%, higher than that of the CycleGAN at 94.3% and the 3DUNet at 96.2%. Among the three models, the GhostUNet model had the fewest parameters (4.27 million) and the shortest training time (99 s per epoch) but achieved the best denoising results. CONCLUSION: The end-to-end deep network GhostUNet outperforms the CycleGAN, 3DUNet models in denoising MC dose distributions for carbon ion radiotherapy. The network requires less than 5 s to denoise a sample of MC simulation with few particles to obtain a qualitative and quantitative result comparable to the dose distribution simulated by MC with relatively large number particles, offering a significant reduction in computation time.

Asunto(s)

RESUMEN

Advanced radiotherapy technology enables the dose to more accurately conform to the tumor target area of the patient, providing accurate treatment for the patient, but the gradient of the patient's radiation dose at the tumor edge is getting larger, which putting forward higher requirements for radiotherapy dose verification. The dose verification system software KylinRay-Dose4D can verify the patient's pre-treatment plan and the in vivo/on-line dose during the patient's treatment, providing important reference for the physicist to modify the radiotherapy plan and ensuring that the patient receives accurate treatment. This study introduces the overall design and key technologies of KylinRay-Dose4D, and tests the pre-treatment plan dose checking calculation and 2D/3D dose verification through clinical cases. The test results showed that the 2D/3D gamma pass rate (3 mm/3%) of KylinRay-Dose4D reconstructed dose compared with TPS plan dose and measured dose is larger than 95%, which indicating that the reconstructed dose of KylinRay-Dose4D meets the requirement of clinical application.

Asunto(s)

RESUMEN

To investigate the γ pass rate limit of plan verification equipment for volumetric modulated arc therapy (VMAT) plan verification and its sensitivity on the opening and closing errors of multi-leaf collimator (MLC), 50 cases of nasopharyngeal carcinoma VMAT plan with clockwise and counterclockwise full arcs were randomly selected. Eight kinds of MLC opening and closing errors were introduced in 10 cases of them, and 80 plans with errors were generated. Firstly, the plan verification was conducted in the form of field-by-field measurement and true composite measurement. The γ analysis with the criteria of 3% dose difference, distance to agreement of 2 mm, 10% dose threshold, and absolute dose global normalized conditions were performed for these fields. Then gradient analysis was used to investigate the sensitivity of field-by-field measurement and true composite measurement on MLC opening and closing errors, and the receiver operating characteristic curve (ROC) was used to investigate the optimal threshold of γ pass rate for identifying errors. Tolerance limits and action limits for γ pass rates were calculated using statistical process control (SPC) method for another 40 cases. The error identification ability using the tolerance limit calculated by SPC method and the universal tolerance limit (95%) were compared with using the optimal threshold of ROC. The results show that for the true composite measurement, the clockwise arc and the counterclockwise arc, the descent gradients of the γ passing rate with per millimeter MLC opening error are 10.61%, 7.62% and 6.66%, respectively, and the descent gradients with per millimeter MLC closing error are 9.75%, 7.36% and 6.37%, respectively. The optimal thresholds obtained by the ROC method are 99.35%, 97.95% and 98.25%, respectively, and the tolerance limits obtained by the SPC method are 98.98%, 97.74% and 98.62%, respectively. The tolerance limit calculated by SPC method is close to the optimal threshold of ROC, both of which could identify all errors of ±2 mm, while the universal tolerance limit can only partially identify them, indicating that the universal tolerance limit is not sensitive on some large errors. Therefore, considering the factors such as ease of use and accuracy, it is suggested to use the true composite measurement in clinical practice, and to formulate tolerance limits and action limits suitable for the actual process of the institution based on the SPC method. In conclusion, it is expected that the results of this study can provide some references for institutions to optimize the radiotherapy plan verification process, set appropriate pass rate limit, and promote the standardization of plan verification.

Asunto(s)

RESUMEN

To investigate the γ pass rate limit of plan verification equipment for volumetric modulated arc therapy (VMAT) plan verification and its sensitivity on the opening and closing errors of multi-leaf collimator (MLC), 50 cases of nasopharyngeal carcinoma VMAT plan with clockwise and counterclockwise full arcs were randomly selected. Eight kinds of MLC opening and closing errors were introduced in 10 cases of them, and 80 plans with errors were generated. Firstly, the plan verification was conducted in the form of field-by-field measurement and true composite measurement. The γ analysis with the criteria of 3% dose difference, distance to agreement of 2 mm, 10% dose threshold, and absolute dose global normalized conditions were performed for these fields. Then gradient analysis was used to investigate the sensitivity of field-by-field measurement and true composite measurement on MLC opening and closing errors, and the receiver operating characteristic curve (ROC) was used to investigate the optimal threshold of γ pass rate for identifying errors. Tolerance limits and action limits for γ pass rates were calculated using statistical process control (SPC) method for another 40 cases. The error identification ability using the tolerance limit calculated by SPC method and the universal tolerance limit (95%) were compared with using the optimal threshold of ROC. The results show that for the true composite measurement, the clockwise arc and the counterclockwise arc, the descent gradients of the γ passing rate with per millimeter MLC opening error are 10.61%, 7.62% and 6.66%, respectively, and the descent gradients with per millimeter MLC closing error are 9.75%, 7.36% and 6.37%, respectively. The optimal thresholds obtained by the ROC method are 99.35%, 97.95% and 98.25%, respectively, and the tolerance limits obtained by the SPC method are 98.98%, 97.74% and 98.62%, respectively. The tolerance limit calculated by SPC method is close to the optimal threshold of ROC, both of which could identify all errors of ±2 mm, while the universal tolerance limit can only partially identify them, indicating that the universal tolerance limit is not sensitive on some large errors. Therefore, considering the factors such as ease of use and accuracy, it is suggested to use the true composite measurement in clinical practice, and to formulate tolerance limits and action limits suitable for the actual process of the institution based on the SPC method. In conclusion, it is expected that the results of this study can provide some references for institutions to optimize the radiotherapy plan verification process, set appropriate pass rate limit, and promote the standardization of plan verification.

Asunto(s)

RESUMEN

PURPOSE: In this study, we performed biological verification measurements of cell survival of a 12C ion irradiation plan employing a high-resolution 3D culture setup. This allowed, in particular, to access the cell inactivation in the low-dose regions close to the target area. MATERIALS AND METHODS: We established the protocol for a 3D culture setup where xrs-5 cells were grown inside a layered matrigel structure in 384-well plates. Their radiosensitivity to conventional and 12C ion radiation was evaluated by irradiating them either with 250 kV X-rays at GSI or with monoenergetic 12C beams of 110 MeV/u at MIT, and compared with those of monolayers. A treatment plan for a rectangular target was prepared using the GSI research treatment planning system TRiP98. xrs-5 cells were seeded in the matrigel-based setup and irradiated in dose fall-off regions using active scanning 12C ion beams. In addition, film dosimetry utilizing radiochromic EBT3 film has been performed to assess the field homogeneity downstream of 384-well V-bottom plates with or without additional agarose coating of the well plate bottom. RESULTS: Dose response curves following X-ray and 12C ion irradiation had linear shape and showed a significant decrease in survival fraction at even moderate doses. Survival measurements in the low-dose regions of the plan for the extended target showed good agreement to the predicted survival fraction. The irradiated film profiles yielded a flat dose distribution without apparent artifacts or inhomogeneities for well plates both with and without agarose coating, confirming the suitability of the experimental setup. CONCLUSIONS: We conclude that the V-bottom 384-well plates in combination with the radiation-sensitive xrs-5 cell line constitute a suitable radiobiological verification tool which can be used especially for low doses. Furthermore, the measured survival of xrs-5 cells show a good agreement with the expected survival in the low-dose out-of-field regions, both laterally and downstream of the target.

Asunto(s)

RESUMEN

Advanced radiotherapy technology enables the dose to more accurately conform to the tumor target area of the patient, providing accurate treatment for the patient, but the gradient of the patient's radiation dose at the tumor edge is getting larger, which putting forward higher requirements for radiotherapy dose verification. The dose verification system software KylinRay-Dose4D can verify the patient's pre-treatment plan and the in vivo/on-line dose during the patient's treatment, providing important reference for the physicist to modify the radiotherapy plan and ensuring that the patient receives accurate treatment. This study introduces the overall design and key technologies of KylinRay-Dose4D, and tests the pre-treatment plan dose checking calculation and 2D/3D dose verification through clinical cases. The test results showed that the 2D/3D gamma pass rate (3 mm/3%) of KylinRay-Dose4D reconstructed dose compared with TPS plan dose and measured dose is larger than 95%, which indicating that the reconstructed dose of KylinRay-Dose4D meets the requirement of clinical application.

Asunto(s)

RESUMEN

OBJECTIVE: To investigate the influence of positioning accuracy of the multi-leaf collimators (MLC) on the passing rate of the plan dose verification for volumetric modulation arc therapy (VMAT) of cervical cancer using an Elekta linear accelerator. METHODS: The dose distributions were measured using Sun Nuclear's Mapcheck and Arccheck semiconductors matrix before and after MLC calibration in30 cervical cancer patients undergoing VMAT. Dosimetric comparisons were performed with 2D and 3D gamma passing rates of 3%, 3 mm and 2%, and 2 mm. The 3D gamma distribution was reconstructed with respect to the patient's anatomy using 3DVH software to evaluate the possible influence of MLC positioning accuracy. RESULTS: Before and after MLC calibration, the gamma passing rates of Mapcheck were (88.80±1.81)% and (99.25 ± 0.53)% under 3% and 3 mm standard, respectively, with an average increase of 10.45%. The corresponding gamma passing rates of Arccheck were (87.61±1.98)% and (98.13±0.99)%, respectively, with an average increase of 10.52%. The gamma passing rates of 3DVH were (89.87±2.28)% and (98.3±1.15)%, respectively, with an average increase of 8.43%. CONCLUSION: The MLC positioning accuracy is one of the main factors influencing dosimetric accuracy of VMAT for cervical cancer. The application of Autocal software facilitates MLC calibration and improves the accuracy and safety of VMAT delivery for cervical cancer.

Asunto(s)

RESUMEN

Objective:To study the impact of the Varian real-time position management (RPM) respiratory gating system on radiotherapy planning dosimetry.Methods:The radiotherapy plans of 40 cases with thoracic or abdominal tumors were retrospectively selected in this study. The motion phantom for quality control was adopted to generate respiratory gating signals, and the 30%-60% stable phase at the end of expiratory was selected as the respiratory gating window. The dose verification for the abovementioned radiotherapy plans was performed using the Portal Dosimetry (PD) system under RPM respiratory gating mode with the Edge accelerator. Afterwards, dose analysis was performed with different γ passing rate criteria and the distribution characteristics of γ values were analyzed. Finally, the verification results between the non-gating mode and the gating mode were compared.Results:Under the respiratory gating mode, the passing rates of all intensity-modulated radiation therapy/volumetric-modulated arc therapy (IMRT/VMAT) plans with or without flattening filters were over 95.5% by γ criteria of (3%, 3 mm) or (3%, 2 mm) and were over 90% by stricter γ criteria of (2%, 2 mm). All plans met the clinical requirements recommended by the American Association of Physicists in Medicine (AAPM). The passing rates of dose verification under non-gating mode were slightly better than those under respiratory gating mode, and the differences between the two modes were statistically significant (3%/3 mm, Z =-1.45; 3%/2 mm, Z =-2.86; 2%/2 mm, Z =-3.70; 1%/1 mm, Z =-4.52; P<0.05). There was no significant difference in the minimum and maximum values of γ and the share of γ > 1.5 of plan verification result under the two modes. However, the average value and standard deviation of the γ were generally smaller under the non-gating mode. Conclusions:The impact of the introduction of RPM respiratory gating technology on dose is clinically acceptable, and the execution of these plans in this gating mode is safe and reliable.

RESUMEN

OBJECTIVE@#To investigate the influence of positioning accuracy of the multi-leaf collimators (MLC) on the passing rate of the plan dose verification for volumetric modulation arc therapy (VMAT) of cervical cancer using an Elekta linear accelerator.@*METHODS@#The dose distributions were measured using Sun Nuclear's Mapcheck and Arccheck semiconductors matrix before and after MLC calibration in30 cervical cancer patients undergoing VMAT. Dosimetric comparisons were performed with 2D and 3D gamma passing rates of 3%, 3 mm and 2%, and 2 mm. The 3D gamma distribution was reconstructed with respect to the patient's anatomy using 3DVH software to evaluate the possible influence of MLC positioning accuracy.@*RESULTS@#Before and after MLC calibration, the gamma passing rates of Mapcheck were (88.80±1.81)% and (99.25 ± 0.53)% under 3% and 3 mm standard, respectively, with an average increase of 10.45%. The corresponding gamma passing rates of Arccheck were (87.61±1.98)% and (98.13±0.99)%, respectively, with an average increase of 10.52%. The gamma passing rates of 3DVH were (89.87±2.28)% and (98.3±1.15)%, respectively, with an average increase of 8.43%.@*CONCLUSION@#The MLC positioning accuracy is one of the main factors influencing dosimetric accuracy of VMAT for cervical cancer. The application of Autocal software facilitates MLC calibration and improves the accuracy and safety of VMAT delivery for cervical cancer.

Asunto(s)

RESUMEN

For scanning beam particle therapy, the plan delivery accuracy is affected by spot size deviation, position deviation and particle number deviation. Until now, all plan verification systems available for particle therapy have been designed for pretreatment verification. The purpose of this study is to introduce a method for online plan delivery accuracy checks and to evaluate the sensitivity of plan delivery accuracy to different beam parameter errors. A program was developed using MATLAB to reconstruct doses from beam parameters recorded in log files and to compare them with the doses calculated by treatment planning system (TPS). Both carbon ion plans and proton plans were evaluated in this study. The dose reconstruction algorithm is verified by comparing the dose from the TPS with the reconstructed dose under the same beam parameters. The sensitivity of plan delivery accuracy to different beam parameter errors was analyzed by comparing the dose reconstructed from the pseudo plans that manually added errors with the original plan dose. For the validation of dose reconstruction algorithm, mean dose difference between the reconstructed dose and the plan dose were 0.70% ± 0.24% and 0.51% ± 0.25% for carbon ion beam and proton beam, respectively. According to our simulation, the delivery accuracy of the carbon ion plan is more sensitive to spot position deviation and particle number deviation, and the delivery accuracy of the proton plan is more sensitive to spot size deviation. To achieve a 90% gamma pass rate with 3 mm/3% criteria, the average spot size deviation, position deviation, particle number deviation should be within 23%, 1.9 mm, and 1.5% and 20%, 2.1 mm, and 1.6% for carbon ion beam and proton beam, respectively. In conclusion, the method that we introduced for online plan delivery verification is feasible and reliable. The sensitivity of plan delivery accuracy to different errors was clarified for our system. The methods used in this study can be easily repeated in other particle therapy centers.

RESUMEN

PURPOSE: The introduction of advanced treatment techniques in proton therapy, such as intensity-modulated proton therapy, leads to an increased need for patient-specific quality assurance, especially an accurate treatment plan verification becomes inevitable. In this study, signal theoretical analysis of dose distributions in scanned proton therapy is performed to investigate the feasibility and limits of two-dimensional (2D) detector arrays for treatment plan verification. METHODS: 2D detector arrays are characterized by two main aspects: the distance between the single detectors on the array or the sampling frequency; and the lateral response functions of a single detector. The analysis is based on single spots, reference fields and on measured and calculated dose distributions of typical intensity-modulated proton therapy treatment plans with and without range shifter. Measurements were performed with Gafchromic EBT3 films (Ashland Speciality Ingredients G.P., Bridgewater, NJ, USA), the MatriXX PT detector array (IBA Dosimetry, Schwarzenbruck, Germany) and the OCTAVIUS detector array 1500XDR (PTW-Freiburg, Germany) at an IBA Proteus PLUS proton therapy system (Ion Beam Applications, Louvain-la-Neuve, Belgium). Dose calculations were performed with the treatment planning system RayStation 6 or 8 (RaySearch Laboratories, Sweden). RESULTS: The Fourier analysis of the data of the treatment planning system and film measurements show maximum frequencies of 0.06/mm for the plan with range shifter and 0.083/mm for the plan without range shifter. According to the Nyquist theorem, this corresponds to minimum required sampling distances of 8.3 and 6 mm, respectively. By comparison, the sampling distances of the arrays of 7.6 mm (MatriXX PT) and 7.1 mm (OD1500XDR) are sufficient to reconstruct the dose distributions adequately from measurements if range shifters are used, whereas some fields of the plans without range shifter violated the Nyquist requirement. The lateral dose response functions of the single detectors within the arrays have clearly higher frequencies than the treatment plans and thus the volume effect only slightly influences the measurements. Consequently, the array measurements show high gamma passing rates with at least 96 % and a good agreement between the investigated line profiles. CONCLUSION: The results indicate that the detector dimensions and sampling distances of the arrays are in most studied cases adequate not to substantially influence the measurement process when they are used for analyzing typical intensity-modulated proton therapy treatment plans. Nevertheless, clinical conditions have been identified, for instance treatment plans without range shifter, under which the Nyquist theorem is violated such that a full representation of the dose distributions with the measurements is not feasible. In these cases, analysis of measurements is limited to pointwise comparisons.

Asunto(s)

RESUMEN

The continuous delivery of volumetric modulated arc therapy (VMAT) plans is usually approximated by discrete apertures at evenly-spaced gantry angles for dose calculation purposes. This approximation can potentially lead to large dose calculation errors if the gantry angle spacings are large and/or there are large changes in the MLC apertures from one control point (CP) to the next. In this work, we developed a sliding-window (SW) method to improve VMAT dose calculation accuracy. For any 2 adjacent VMAT CPs ni and ni + 1, the dose distribution was approximated by a 2-CP SW IMRT beam with the starting MLC positions at CP ni and ending MLC positions at CP ni + 1, with the gantry angle fixed in the middle of the 2 VMAT CPs. Therefore, a VMAT beam with N CPs was approximated by a SW plan with N-1 SW beams. To validate the method, VMAT plans were generated for 10 patients in Pinnacle using 4° gantry spacing. Each plan was converted to a SW plan and dose was recalculated. Another VMAT plan, with 1° gantry spacing, was created by interpolating the original VMAT beam. The original plans were delivered on an Elekta Versa HD and measured with ArcCHECK. For both the isodose distribution and DVH, there were significant differences between the original VMAT plan and either the SW or the interpolated plan. However, they were indistinguishable between the SW and the interpolated plans. When compared with measurement, the average passing rates of the original VMAT plans were 87.3 ± 2.8% and 93.1 ± 1.0% for the 5 HN and 5 spine SBRT cases, respectively. On the other hand, the passing rates for both the VMAT1 and SW plans were above 95% for all the 10 cases studied. The dose calculation times of the original VMAT plans and the SW plans were very similar. We conclude that the proposed SW approach improves VMAT dose calculation accuracy without increase in dose calculation time.

Asunto(s)

RESUMEN

Objective To investigate the optimal thresholds of the passing rate with different gamma measurement criteria (percent dose difference/DTA) based on the Delta 4 three-dimensional dosimetric verification system in the verification of volumetric modulated arc-therapy (VMAT) plan for cervical cancer.Methods Thirty clinically-approved dual-arc VMAT plans using the RapidArcTM (Varian Medical Systems Inc.) for cervical cancer were randomly selected.The gamma analysis and dose-volume histogram (DVH) evaluation were performed using Delta 4.All the plans were classified according to the following two criteria:1.If the absolute percentage dose errors of all specific dosimetry indices on the DVH were less than 5％,the plan was regarded as clinically acceptable.2.If the gamma passing rate was 90％ or 95％ under the criteria of 2％/2 mm and 3％/3 mm,the plan was regarded as acceptable.The sensitivity and specificity analyses were conducted based on the classification results and the receiver operating characteristic (ROC) curve was plotted.By calculating the Youden Index,the optimal thresholds under different Gamma criteria (global and local 2％/2 mm and 3％/3 mm) were investigated.Finally,the ability of distinguishing the plan was clinically acceptable or not between the conventional and optimal thresholds was quantitatively compared according to the sensitivity and specificity analyses.Results The optimal thresholds under the global 3％/3 mm and 2％/2 mm criteria were 98.3％ and 87.05％;and 97.55％ 、86.05％ for the local gamma analysis.Compared with the conventional thresholds,the sensitivity of the optimal thresholds was 0.93 by using the global and local gamma analyses under the 3％/3 mm criterion.Under the 2％/2 mm criterion,the sensitivity of the optimal thresholds was 0.65 and the specificity was 0.49 by using the global gamma analysis.The sensitivity was 0.7 and the specificity was 0.46 by using the local gamma analysis,suggesting that the sensitivity and the specificity were more balanced under the 2％/2 mm criterion.Conclusions Application of the optimal thresholds in the verification of VMAT plans can maintain the balance between the sensitivity and specificity,prevent the harm of clinically unacceptable plans to patients to certain extent and reduce the probability of increasing the daily work load for physicists due to the misjudgement of clinically acceptable plans.

RESUMEN

The combined effects of lung tumor motion and limitations of treatment planning system dose calculations in lung regions increases uncertainty in dose delivered to the tumor and surrounding normal tissues in lung stereotactic body radiotherapy (SBRT). This study investigated the effect on plan quality and accuracy when overriding treatment volume electron density values. The QUASAR phantom with modified cork cylindrical inserts, each containing a simulated spherical tumor of 15-mm, 22-mm, or 30-mm diameter, was used to simulate lung tumor motion. Using Monaco 5.1 treatment planning software, two standard plans (50% central phase (50%) and average intensity projection (AIP)) were compared to eight electron density overridden plans that focused on different target volumes (internal target volume (ITV), planning target volume (PTV), and a hybrid plan (HPTV)). The target volumes were set to a variety of electron densities between lung and water equivalence. Minimal differences were seen in the 30-mm tumor in terms of target coverage, plan conformity, and improved dosimetric accuracy. For the smaller tumors, a PTV override showed improved target coverage as well as better plan conformity compared to the baseline plans. The ITV plans showed the highest gamma pass rate agreement between treatment planning system (TPS) and measured dose (P < 0.040). However, the low electron density PTV and HPTV plans also showed improved gamma pass rates (P < 0.035, P < 0.011). Low-density PTV overrides improved the plan quality and accuracy for tumor diameters less than 22 mm only. Although an ITV override generated the most significant increase in accuracy, the low-density PTV plans had the additional benefit of plan quality improvement. Although this study and others agreed that density overrides improve the treatment of SBRT, the optimal density override and the conditions under which it should be applied were found to be department specific, due to variations in commissioning and calculation methods.

Asunto(s)

RESUMEN

PURPOSE: Brachytherapy procedure may result in acute tissue reactions like edema, causing deviations between planned and measured doses. The rationale for in vivo dosimetry in interstitial brachytherapy is to assess the accuracy of the delivered dose in comparison with the dose calculated by the treatment planning system (TPS). MATERIAL AND METHODS: One single computer tomography (CT) dataset was used for brachytherapy planning, taken within 24 hours after implantation. In vivo interstitial measurements with micro-MOSFET-detectors (metal oxide semiconductor field effect transistor) were performed in 12 patients with different anatomic locations of cancers, including thorax-wall, head and neck, breast, and different types of implantations (monoplanar, loops, and multiplanar). RESULTS: Measured values for the thorax-wall tumor patient showed a good agreement with the calculated data, with average deviation of -2.7% in 8 mm distance to the closest dwell position of the source. The deviation of the measured dose value of the head and neck patient was +55.6% in the first fraction and +8.5% in the last fraction. In the ten breast cancer patients, measured doses depended on the proximity of the detector to the irradiated volume PTV. CONCLUSIONS: The deviations between planned and measured dose values were markedly influenced by the proximity of the detector to the PTV because where the edema exerts, the greatest influence on the tube applicator geometry. The positioning of the patient during irradiation must correspond to the positioning in the planning CT. Further studies are needed to investigate the role of in vivo dosimetry during interstitial brachytherapy as a routine procedure.

RESUMEN

BACKGROUND AND PURPOSE: The novel MatriXXFFF (IBA Dosimetry, Germany) detector is a new 2D ionization chamber detector array designed for patient specific IMRT-plan verification including flattening-filter-free (FFF) beams. This study provides a detailed analysis of the characterization and clinical evaluation of the new detector array. MATERIAL AND METHODS: The verification of the MatriXXFFF was subdivided into (i) physical dosimetric tests including dose linearity, dose rate dependency and output factor measurements and (ii) patient specific IMRT pre-treatment plan verifications. The MatriXXFFF measurements were compared to the calculated dose distribution of a commissioned treatment planning system by gamma index and dose difference evaluations for 18 IMRT-sequences. All IMRT-sequences were measured with original gantry angles and with collapsing all beams to 0° gantry angle to exclude the influence of the detector's angle dependency. RESULTS: The MatriXXFFF was found to be linear and dose rate independent for all investigated modalities (deviations ≤0.6%). Furthermore, the output measurements of the MatriXXFFF were in very good agreement to reference measurements (deviations ≤1.8%). For the clinical evaluation an average pixel passing rate for γ(3%,3mm) of (98.5±1.5)% was achieved when applying a gantry angle correction. Also, with collapsing all beams to 0° gantry angle an excellent agreement to the calculated dose distribution was observed (γ(3%,3mm)=(99.1±1.1)%). CONCLUSIONS: The MatriXXFFF fulfills all physical requirements in terms of dosimetric accuracy. Furthermore, the evaluation of the IMRT-plan measurements showed that the detector particularly together with the gantry angle correction is a reliable device for IMRT-plan verification including FFF.

Asunto(s)

RESUMEN

Objective To investigate the effect of the angle correction factors of ionization chamber array Matrixx on the dosimetric verification of volumetric modulated arc therapy plan.Methods The Matrixx (IBA)was put in the middle of the MultiCube Phantom. Computed tomography scan was performed and the results were sent to the Raystation treatment planning system(TPS). All data calculated from TPS and actually measured using MatriXX were gained under the following conditions:6 MV,100 MU,28 cm×28 cm radiation field. And the directions of beam were from 0°to 180°with an interval of 5°(except an interval of 1° from 85° to 95°). The angle correction factors(CF)(θ)cor of MatriXX were calculated by the calculated dose values from TPS and the measured values using MatriXX and then mirrored to the opposite side. CF (θ)cor values were compared with CF(θ)def values that were given by manufacturer. The comparison was made by paired t-test. Results CF(θ)cor and CF(θ)def were different, and the difference was significant between 85° and 95°,with a maximum of 7.5%(P<0.05). The CF(θ)cor correction method had a higher gamma pass rate than the CF(θ)def correction method,with a maximum of 17%(P<0.05). Conclusions The ionization chamber array MatriXX has an angular dependence and the angle correction should be performed.The angle correction factors have the individual characteristics and are different in every unit ionization chamber of the MatriXX. Therefore, it is necessary to do angle correction for every unit ionization chamber of the MatriXX and the possible errors caused by various factors should be considered in order to improve the accuracy rate and gamma pass rate of the plan verification.